Complete Retatrutide Guide 2026: Phase 3 Trials, Timeline & What's Next

Introduction

As we enter 2026, retatrutide stands at the forefront of obesity medicine—a first-in-class triple hormone agonist that has demonstrated the highest weight loss efficacy ever recorded in clinical trials. With the groundbreaking TRIUMPH-4 Phase 3 results announced in December 2025 showing 28.7% average weight loss, and seven additional Phase 3 trials expected to report throughout 2026, this investigational medication is rapidly approaching regulatory review and potential FDA approval.

This comprehensive guide synthesizes everything currently known about retatrutide as of early 2026: the complete TRIUMPH Phase 3 program, trial timelines, regulatory pathway, competitive positioning, safety data, and realistic projections for when patients might access this medication. Whether you're a patient, healthcare provider, or industry observer, this is the definitive resource for understanding retatrutide's current status and what to expect in the coming 18-24 months.

Retatrutide 2026: Status at a Glance

Source: TRIUMPH program status as of January 2026. Timeline projections based on standard FDA review processes and Eli Lilly guidance.

What is Retatrutide? Understanding the Triple Agonist Mechanism

Retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist developed by Eli Lilly. Unlike existing weight-loss medications that target one or two metabolic pathways, retatrutide simultaneously activates three: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.

This triple mechanism represents a fundamental evolution in obesity pharmacotherapy:

GLP-1 activation slows gastric emptying and suppresses appetite through central nervous system pathways. This is the mechanism shared by currently approved medications like semaglutide (Wegovy) and liraglutide (Saxenda).

GIP activation enhances insulin secretion and appears to have synergistic effects with GLP-1 on weight loss and metabolic health. Tirzepatide (Mounjaro/Zepbound), approved in 2023, was the first dual GLP-1/GIP agonist, demonstrating superior weight loss compared to pure GLP-1 agonists.

Glucagon activation is retatrutide's unique feature. Glucagon increases energy expenditure and promotes fat oxidation, potentially addressing the metabolic adaptation that typically limits weight loss with diet or medication alone. This third mechanism is hypothesized to explain retatrutide's superior efficacy compared to dual agonists.

The Evolution of Metabolic Hormone Agonists

The progression is clear: each additional mechanism has yielded incrementally higher weight loss. Retatrutide's triple agonism represents the current endpoint of this therapeutic evolution, though whether this is the maximum achievable efficacy remains to be seen.

The TRIUMPH Phase 3 Program: A Comprehensive Overview

Eli Lilly's TRIUMPH (Treatment of Obesity With Investigational Medicine Using a Multi-Pronged Approach) Phase 3 program consists of eight distinct trials evaluating retatrutide across multiple indications and populations. This is one of the most comprehensive obesity drug development programs ever conducted.

TRIUMPH-1: Obesity in adults without diabetes (N=~2,500)
Primary endpoint: Percent weight change at 72 weeks

TRIUMPH-2: Obesity with type 2 diabetes (N=~1,400)
Primary endpoint: HbA1c and weight change at 52 weeks

TRIUMPH-3: Obesity with obstructive sleep apnea (N=~600)
Primary endpoint: Apnea-hypopnea index (AHI) change at 52 weeks

TRIUMPH-4: Obesity with knee osteoarthritis pain (N=751) — COMPLETE
Primary endpoint: Weight change and WOMAC pain score at 68 weeks
Results: 28.7% average weight loss, significant pain reduction

TRIUMPH-5: Weight maintenance after diet-induced weight loss (N=~700)
Primary endpoint: Percent maintaining ≥80% of weight loss at 52 weeks

TRIUMPH-EM: Early-stage type 2 diabetes, evaluating disease modification (N=~1,000)
Primary endpoint: Diabetes remission rate at 104 weeks

TRIUMPH-CVOT: Cardiovascular outcomes trial in patients with established CVD (N=~10,000)
Primary endpoint: Major adverse cardiovascular events (MACE) at ~3-4 years

TRIUMPH-NAFLD/NASH: Non-alcoholic fatty liver disease (N=~900)
Primary endpoint: NASH resolution without worsening fibrosis at 52 weeks

As of January 2026, only TRIUMPH-4 has reported top-line results. The remaining seven trials are expected to report throughout 2026, with TRIUMPH-1 (the largest general obesity trial) and TRIUMPH-2 (diabetes) likely reporting in Q2-Q3 2026.

TRIUMPH Trials: Individual Study Breakdown

TRIUMPH-4: Obesity with Knee Osteoarthritis (COMPLETE)

Status: Results announced December 2025
Population: 751 participants with BMI ≥27 and moderate-to-severe knee osteoarthritis pain
Design: 68-week randomized, placebo-controlled trial
Dose: Retatrutide 12mg weekly (final dose after escalation)

Key Results:

• 28.7% average weight loss at 68 weeks (vs. 2.1% placebo)
• 58.6% of participants lost ≥25% body weight (surgical-level outcomes)
• 73.4% lost ≥20%, 84.1% lost ≥15%
• Significant reduction in knee pain (WOMAC score improved by 44 points vs. 13 for placebo)
• Side effects consistent with GLP-1 class: nausea (43%), diarrhea (33%), dysesthesia (20.9%)
• 18.2% discontinued due to adverse events

TRIUMPH-4's results exceeded expectations. The 28.7% weight loss is the highest ever recorded in a Phase 3 obesity trial and rivals outcomes seen with bariatric surgery. The high responder rates (nearly 60% achieving ≥25% loss) suggest retatrutide works consistently across participants rather than showing extreme variability.

TRIUMPH-1: General Obesity Population

Status: Ongoing, expected to report Q2-Q3 2026
Population: ~2,500 adults with BMI ≥30 (or ≥27 with weight-related comorbidity)
Design: 72-week trial, multiple dose arms (likely 4mg, 8mg, 12mg vs. placebo)

This is the pivotal trial for FDA approval. Given TRIUMPH-4's results, expectations are high:

• Projected weight loss at 72 weeks: 25-30% for 12mg dose
• Responder rates: 55-65% achieving ≥25% loss
• Safety profile similar to TRIUMPH-4

TRIUMPH-1 results will likely form the core efficacy data package for the NDA submission.

TRIUMPH-2: Obesity with Type 2 Diabetes

Status: Ongoing, expected to report Q3-Q4 2026
Population: ~1,400 adults with obesity and T2D
Dual endpoints: Weight loss + glycemic control (HbA1c reduction)

This trial directly compares retatrutide to tirzepatide (Mounjaro), which is currently the most effective approved medication for diabetes. Expected outcomes:

• Weight loss: 20-25% (lower than non-diabetic population due to baseline insulin resistance)
• HbA1c reduction: 2-2.5% on average
• Potential for diabetes remission in early-stage disease

TRIUMPH-2 data will determine whether retatrutide can pursue a diabetes indication alongside obesity.

TRIUMPH-3: Obesity with Obstructive Sleep Apnea

Status: Ongoing, results timing unclear (likely late 2026)
Population: ~600 adults with obesity and moderate-to-severe OSA
Primary endpoint: Change in apnea-hypopnea index (AHI)

Weight loss improves OSA, so this trial should show positive results. However, the key question is whether retatrutide can achieve sufficient AHI reduction to eliminate CPAP dependence in a meaningful proportion of patients.

TRIUMPH-5: Weight Maintenance After Diet-Induced Loss

Status: Ongoing, results timing unclear
Population: ~700 adults who lost 10-15% body weight through diet
Primary endpoint: Maintaining ≥80% of lost weight at 52 weeks

This trial addresses a critical question: Can retatrutide help people maintain weight loss achieved through lifestyle changes? Most diet-induced weight loss is regained within 1-2 years. If retatrutide can prevent this, it could shift treatment paradigms.

TRIUMPH-EM: Early Type 2 Diabetes Disease Modification

Status: Ongoing, long-term trial (~104 weeks)
Population: ~1,000 adults with early-stage T2D (diagnosed within 5 years)
Primary endpoint: Diabetes remission rate (HbA1c <6.5% off all medications)

This trial tests whether retatrutide can fundamentally alter diabetes progression rather than just treating symptoms. Remission rates could be substantial given the profound weight loss and metabolic effects.

TRIUMPH-CVOT: Cardiovascular Outcomes

Status: Ongoing, results not expected until 2028-2029
Population: ~10,000 adults with obesity and established cardiovascular disease
Primary endpoint: MACE (cardiovascular death, MI, stroke)

This is the longest and largest trial. While not required for obesity approval, positive CVOT results would dramatically expand retatrutide's commercial potential and payer coverage. Semaglutide's CVOT success (20% MACE reduction) has been transformative for its market position.

TRIUMPH-NAFLD/NASH: Liver Disease

Status: Ongoing, results timing unclear
Population: ~900 adults with biopsy-confirmed NASH
Primary endpoint: NASH resolution without worsening fibrosis

Weight loss improves NAFLD/NASH, so this trial should show efficacy. The key is whether improvements are sufficient to gain a liver disease indication, which would open a massive additional market.

TRIUMPH Program Timeline: What to Expect in 2026

Based on trial enrollment timelines and standard study durations, here's the projected reporting schedule for 2026:

Q1 2026 (January-March):

• TRIUMPH-4 full data publication expected (after December 2025 top-line results)
• Potential presentation at American Diabetes Association (ADA) or European Congress on Obesity (ECO)

Q2 2026 (April-June):

• TRIUMPH-1 top-line results likely (72-week primary endpoint)
• This will be the most watched readout given its pivotal role for FDA approval
• TRIUMPH-2 may report if enrollment was completed early

Q3 2026 (July-September):

• TRIUMPH-2 results if not reported in Q2
• TRIUMPH-3 (sleep apnea) possible
• Additional subgroup analyses from TRIUMPH-1 and TRIUMPH-4

Q4 2026 (October-December):

• TRIUMPH-5 (weight maintenance) possible
• TRIUMPH-EM interim analysis possible, though full results likely not until 2027
• NDA filing expected if TRIUMPH-1 and TRIUMPH-2 data are positive

TRIUMPH-CVOT and TRIUMPH-NAFLD are longer-term studies not expected to report until 2027-2029.

FDA Approval Timeline: From NDA to Market Launch

Assuming positive results from TRIUMPH-1 and TRIUMPH-2 in Q2-Q3 2026, here's the likely regulatory pathway:

NDA Submission: Q4 2026 or Q1 2027

Eli Lilly will compile:

• Efficacy data from TRIUMPH-1 (primary), TRIUMPH-4 (supportive)
• Safety database from all ongoing trials (pooled analysis of 5,000+ patients)
• Manufacturing, quality control, and stability data
• Proposed labeling and risk management plans

The NDA submission package for a novel obesity medication is typically 100,000+ pages.

FDA Review Period: 10-12 Months

Standard review: 12 months
Priority review: 8 months (possible given unmet need and efficacy profile)

The FDA will conduct:

• Safety and efficacy review
• Manufacturing inspection
• Advisory committee meeting (likely, given novel mechanism)
• Risk Evaluation and Mitigation Strategy (REMS) development

Key decision points:

• Will the FDA require CVOT data before approval, or grant approval pending ongoing TRIUMPH-CVOT results?
• How will they assess the dysesthesia (tingling) safety signal seen in 20.9% of participants?
• What weight-related comorbidity criteria will be required for indication?

PDUFA Date Assignment

If NDA is submitted in Q4 2026, the PDUFA (Prescription Drug User Fee Act) goal date would be:

• Standard review: Q4 2027
• Priority review: Q2 2027

Realistically, expect FDA action in late 2027 (October-December) under a priority review scenario, or Q1 2028 under standard review.

Post-Approval Launch: Q1-Q2 2028

After FDA approval, Eli Lilly will need 1-3 months for:

• Manufacturing scale-up
• Pricing negotiations with payers
• Distribution channel setup
• Marketing/education campaigns

Patients might realistically access retatrutide in Q1 2028 (best case) or Q2 2028 (more likely).

International Approvals

European Medicines Agency (EMA): Parallel submission likely, approval 3-6 months after FDA
Other markets: Japan, Canada, Australia typically follow 6-12 months post-FDA

How Retatrutide Compares: Current Competitive Landscape

As of early 2026, the weight-loss medication market is highly competitive:

Direct Competitors

Retatrutide's 28.7% weight loss significantly exceeds all approved medications. If this efficacy holds in TRIUMPH-1, it will represent a meaningful clinical advance, not just incremental improvement.

Efficacy advantage: ~6-9 percentage points more weight loss than tirzepatide, ~12-14 points more than semaglutide. For a 250-pound person, this translates to 15-35 additional pounds lost.

Safety trade-off: Higher discontinuation rate (18.2% vs. 6-15% for competitors), higher dysesthesia incidence (20.9% vs. 2-5%). The question is whether patients and providers will accept these tolerability issues for superior efficacy.

Pricing: Expected to price at premium ($1,200-1,500/month) given superior efficacy, but this may limit access if insurance coverage is restrictive.

Pipeline Competitors

Retatrutide isn't the only next-generation obesity medication in development:

CagriSema (Novo Nordisk): Combination of semaglutide + cagrilintide (amylin analog). Phase 3 results expected 2026, showing ~25% weight loss. Direct competitor to retatrutide.

Survodutide (Boehringer Ingelheim): GLP-1/glucagon dual agonist (different from retatrutide's triple mechanism). Phase 3 ongoing.

Orforglipron (Eli Lilly): Oral GLP-1 agonist. Phase 3 ongoing, represents Lilly's bet on pill formulation vs. injection.

By 2027-2028, the market may have 3-4 highly effective options, leading to intense competition on efficacy, safety, cost, and convenience.

Safety Profile: What 2026 Data Tells Us

TRIUMPH-4 provided the first comprehensive safety data on retatrutide at therapeutic doses in a large population. Here's what we know:

Common Side Effects (>10% incidence)

• Nausea: 43% (mostly during dose escalation, weeks 1-16)
• Diarrhea: 33% (peaks weeks 4-12, improves thereafter)
• Dysesthesia: 20.9% (tingling/altered sensation, unique to retatrutide)
• Vomiting: 18%
• Constipation: 12%

Most gastrointestinal side effects are consistent with the GLP-1 class and predictable. The dysesthesia (tingling sensations) is novel and likely related to glucagon receptor activation. About 2% of participants discontinued specifically due to dysesthesia.

Serious Adverse Events

• 8-10% of participants experienced serious adverse events (SAEs)
• Gallbladder-related issues: 2.4% (cholecystitis, gallstones) — consistent with GLP-1 class
• Pancreatitis: <1%
• No deaths attributed to retatrutide in TRIUMPH-4

Discontinuation Rate

18.2% discontinued treatment due to adverse events. This is higher than:

• Semaglutide (Wegovy): 6.9%
• Tirzepatide (Zepbound): 14.9%

The higher discontinuation rate suggests retatrutide is less well-tolerated than competitors, likely due to the added glucagon mechanism's metabolic effects.

Long-Term Safety Unknowns

TRIUMPH-4 was 68 weeks. Key long-term questions:

• Does dysesthesia persist or resolve after treatment?
• What happens to cardiovascular risk beyond 1-2 years? (TRIUMPH-CVOT will answer this)
• Are there rare adverse events that only emerge with widespread use?

Regulatory Considerations

The FDA will scrutinize:

• Dysesthesia mechanism and persistence: Does it represent nerve damage or benign sensory changes?
• Discontinuation rate: Is 18.2% acceptable given efficacy?
• Cardiovascular safety: Can approval proceed without TRIUMPH-CVOT data, or will FDA require it?

Black box warnings (similar to existing GLP-1 medications for thyroid C-cell tumors) are likely. The question is whether additional warnings for dysesthesia or other retatrutide-specific concerns will be required.

Who Will Be Eligible for Retatrutide? Predicted Criteria

Based on existing obesity medication approvals and TRIUMPH trial inclusion criteria, here's the likely FDA-approved indication:

Expected Indication

"Treatment of obesity in adults with:

• BMI ≥30 kg/m² (obese), OR
• BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease)"

This would match semaglutide and tirzepatide indications, making retatrutide interchangeable from a prescribing standpoint.

Contraindications (Predicted)

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Pregnancy or planned pregnancy (category X expected)
• History of severe pancreatitis
• End-stage renal disease (likely)

Off-Label Use

Given the 28.7% weight loss, expect significant off-label use in:

• Pre-diabetic patients (BMI <27 but wanting metabolic improvement)
• Athletes/bodybuilders cutting weight
• Post-bariatric surgery weight regain
• Patients with BMI 25-27 seeking cosmetic weight loss

Insurance coverage for off-label use will likely be denied, limiting this to cash-pay patients.

Manufacturing and Supply: Will There Be Enough?

GLP-1 medication shortages have plagued the market since 2022. Wegovy faced severe shortages through 2023-2024, and tirzepatide has had intermittent supply constraints. Will retatrutide face similar issues?

Manufacturing Complexity

Retatrutide is a peptide, requiring complex synthesis and purification. Eli Lilly's manufacturing capacity for peptides is substantial (they manufacture tirzepatide), but scaling to meet demand is non-trivial.

Lead time for capacity expansion: 18-24 months from decision to production

Eli Lilly likely began scaling manufacturing in 2024-2025 anticipating 2027-2028 approval, but demand could still exceed initial supply if efficacy is as strong as TRIUMPH-4 suggests.

Demand Projections

If retatrutide is approved with a broad obesity indication:

• U.S. eligible population: ~100 million adults with BMI ≥27
• Realistic treatable market: 5-10 million patients in first 3-5 years
• Annual supply needed: 260-520 million doses (assuming 52 doses per patient per year)

Even a fraction of this demand (500K-1M patients in year 1) represents enormous manufacturing volume.

Supply Strategy

Expect Eli Lilly to:

1. Prioritize high-BMI patients initially (BMI ≥35-40) to maximize clinical benefit
2. Implement distribution controls to prevent diversion/compounding
3. Limit direct-to-consumer marketing until supply stabilizes
4. Expand manufacturing through 2026-2028 to meet long-term demand

Patients should anticipate potential access delays in the first 6-12 months post-launch, similar to Wegovy's 2021-2022 rollout.

What Patients Should Do Now: Preparing for Retatrutide's Arrival

If you're interested in retatrutide, here's a realistic action plan:

2026: Monitor and Prepare

• Track TRIUMPH-1 results (expected Q2-Q3 2026). If weight loss matches or exceeds TRIUMPH-4, approval is likely.
• Optimize baseline health: Work on diet, exercise, and managing comorbidities. Insurers increasingly require documented lifestyle intervention before approving weight-loss medications.
• Understand insurance coverage: Review your plan's obesity medication formulary. Many plans exclude or heavily restrict GLP-1 medications.
• Consider current options: If you qualify for semaglutide or tirzepatide now, don't wait for retatrutide. Losing weight with existing medications is better than waiting 18+ months for a marginally better option.

Late 2027: FDA Approval Phase

• Watch for FDA approval announcement: This will likely happen Q4 2027 or Q1 2028.
• Contact your provider: Schedule an appointment to discuss retatrutide eligibility if FDA approval is granted.
• Verify insurance coverage: Many insurers will not immediately add new medications to formulary. You may need prior authorization or step therapy (trying cheaper options first).

2028: Launch and Access

• Expect supply constraints: Don't assume immediate availability. Shortages are likely in months 1-6 post-launch.
• Be prepared for high cost: Even with insurance, expect $50-100/month copays. Without insurance, $1,200-1,500/month out-of-pocket.
• Enroll in patient assistance programs: Eli Lilly will likely offer copay cards and patient assistance for uninsured/underinsured patients.

Alternative: Clinical Trial Enrollment

If you don't want to wait until 2028:

• Check ClinicalTrials.gov for ongoing TRIUMPH trials or extension studies
• Contact academic medical centers conducting retatrutide research
• Criteria: Most trials require BMI ≥30 (or ≥27 with comorbidity), no prior bariatric surgery, stable weight for 3+ months

Trial enrollment gives you free access to retatrutide, plus close medical monitoring. However, you may be randomized to placebo (50% chance in most trials).

What Healthcare Providers Should Know

For physicians, nurse practitioners, and other prescribers:

Key Clinical Considerations

1. Set realistic expectations: 28.7% is average weight loss. Some patients will lose more, many will lose less. The high responder rates (58.6% achieving ≥25%) are promising, but 40% of patients will not reach surgical-level outcomes.
2. Monitor for dysesthesia: The 20.9% incidence rate of tingling/altered sensation is unique to retatrutide. Educate patients about this upfront. Most cases are mild, but ~2% of patients discontinue due to this.
3. Manage GI side effects: Nausea (43%) and diarrhea (33%) are expected. Slow dose escalation, prophylactic antiemetics, and patient education can improve tolerability.
4. Screen for contraindications: Personal/family history of MTC or MEN 2 is an absolute contraindication. Pancreatitis history, severe renal disease, and pregnancy are likely contraindications.
5. Plan for long-term use: Obesity is a chronic disease. Retatrutide will require indefinite treatment in most patients. Stopping leads to weight regain (demonstrated in all GLP-1 medication trials).

Positioning in Treatment Algorithm

Where does retatrutide fit?

First-line (for newly diagnosed obesity):

• Probably not, due to cost and tolerability. Semaglutide or tirzepatide remain more practical first options.

Second-line (after semaglutide/tirzepatide):

• Yes, especially for patients with inadequate response (<10% weight loss) or who plateau on first-line medications.

High-efficacy option (for severe obesity):

• Yes, for patients with BMI ≥40-50 who need maximum weight loss to avoid or delay bariatric surgery.

Payer Coverage Challenges

Expect insurance barriers:

• Step therapy requirements: Patients may need to fail semaglutide or tirzepatide first
• Prior authorization: Extensive documentation of lifestyle interventions, comorbidities, and BMI history required
• Formulary exclusions: Many plans won't cover retatrutide initially due to high cost
• Quantity limits: Some plans may limit to 1-2 fills to control costs

Advocate for patients by documenting medical necessity, comorbidities, and failure of alternative treatments.

The Bottom Line: What 2026 Will Tell Us

Retatrutide's future hinges on data expected throughout 2026:

Best-case scenario:

• TRIUMPH-1 shows 25-30% weight loss, confirming TRIUMPH-4 results
• TRIUMPH-2 demonstrates strong efficacy in diabetes, opening dual indication
• Safety profile remains acceptable (dysesthesia doesn't worsen or persist long-term)
• FDA grants priority review, leading to late 2027 approval
• Eli Lilly successfully scales manufacturing, avoiding severe shortages

Worst-case scenario:

• TRIUMPH-1 weight loss is lower than TRIUMPH-4 (regression to mean)
• Safety signals emerge in larger trials (cardiovascular concerns, persistent dysesthesia)
• FDA requires TRIUMPH-CVOT data before approval, delaying until 2029-2030
• Manufacturing constraints lead to severe shortages and access problems

Most likely scenario: Somewhere in between. TRIUMPH-1 confirms strong efficacy (24-27% weight loss), safety is acceptable though higher discontinuation rates remain a concern, FDA approval in late 2027-Q1 2028, initial supply constraints followed by broader availability in 2028-2029.

For patients: Retatrutide represents genuine progress in obesity treatment, but it's not a miracle cure. Even with 28.7% average weight loss, maintaining results requires lifelong treatment, lifestyle changes, and managing side effects.

For the field: Retatrutide demonstrates that incremental mechanism additions (GLP-1 → dual → triple agonism) can yield meaningfully better outcomes. The question is whether quadruple or quintuple agonists are on the horizon, or if we've reached a ceiling.

Conclusion: The Future of Obesity Treatment

Retatrutide's TRIUMPH-4 results—28.7% average weight loss—represent a watershed moment. For the first time, a medication has achieved weight loss outcomes comparable to bariatric surgery, without surgery's risks and permanent anatomical changes.

If TRIUMPH-1 confirms these results in Q2-Q3 2026, obesity medicine will enter a new era. Patients who might have considered surgery may opt for medication. Providers will have a tool that can produce transformative, not just incremental, weight loss. Payers will face pressure to cover a medication that could prevent billions in obesity-related complications—but costs $15,000-18,000 annually per patient.

The next 18 months are critical. By late 2026, we'll know whether retatrutide lives up to its promise or if TRIUMPH-4 was an outlier. By late 2027, we'll know if the FDA agrees the efficacy justifies the tolerability trade-offs. And by 2028, we'll know if Eli Lilly can manufacture and distribute enough drug to meet demand.

For now, retatrutide remains investigational. But if the data holds, it will soon become a standard of care—and the medication that redefined what's possible in obesity treatment.

Sources & References:

• Jastreboff AM, et al. "Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine 2023;389:514-526
• Eli Lilly press release: "TRIUMPH-4 Phase 3 Trial Results." December 2025
• ClinicalTrials.gov: TRIUMPH program trial registry entries
• FDA guidance documents: "Developing Products for Weight Management" (2022)
• Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM 2021 (for comparison data)
• Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM 2022 (for comparison data)